Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 12/6/2007 First Published: 9/23/2005


1.		Phase I/II Study of Nelfinavir Mesylate in Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				CHNMC-04090 NCT00233948

Last Modified: 5/22/2008 First Published: 12/24/2007


2.		Phase I/II Study of Nelfinavir Mesylate in Combination With Concurrent Thoracic Radiotherapy, Cisplatin, and Etoposide in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UPCC-806285 806285, UPCC-04507, NCT00589056


3.		Nelfinavir, a Phase I/Phase II Rectal Cancer Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				MEC 07-03-026 NCT00704600


4.		Study to Evaluate Using Nelfinavir With Chemoradiation for Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				200802788 NCT00791336

Last Modified: 11/24/2008 First Published: 2/12/2007


5.		Phase I Study of Nelfinavir Mesylate in Patients With Metastatic, Refractory, or Recurrent Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-07-C-0047 NCI-P6880, NCT00436735

First Published: 6/24/2008


6.		Phase I Study of Neoadjuvant Therapy Comprising Hypofractionated Stereotactic Radiotherapy and Concurrent Nelfinavir in Combination With Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Patients With Locally Advanced Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				19 and over				NCI				UNMC-44107 441-07, UNMC-441-07-FB, NCT00705393


7.		Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Approved-not yet active				18 to 65				Other				07-09-04/07 EudraCT number 2008-001078-34, NCT00694837

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute